Thursday, August 10, 2017 4:41:03 AM
Buy Quidel Corporation! Insane Upward Trend With Gains Of 25.35% (Article)
Quidel is at a three year high with a pps (price per share) of 34.12
Quidel announced that they have entered into a definitive agreement to acquire Alere Triages' Assets
Made ~$118,189,000 in Gross Profits
The Global Biotechnical Market was valued at $270.5 Billion in 2013
Analysts gave QDEL an average estimate of ~$241.32 million for the expected total revenue in 2018.
Quidel Corporation (QDEL) is a biotechnical company that develops, manufactures, and markets their diagnostic testing solutions for infectious diseases, women's' health products, and gastrointestinal diseases. From their research and development efforts, Quidel has a wide range of products to offer. To begin with, they just received FDA Clearance and CLIA waiver for their award winning point-of-car Sofia 2 Instrument which is used for the rapid detection of respiratory syncytial virus (RSB). Also, the company has recently also gotten FDA Clearance to market their Solana C. difficile Assay for the detection of Clostridium difficile-infection (CDI). Their other products include QuickVue influenza, QuickVue RSV, Quidel Molecular RXV, and much more.
On July 17, 2017, Quidel announced that they have entered into a definitive agreement to acquire Alere Triages' Assets. This will allow Quidel to distribute the Triage MeterPro products and BNP assays which brought the acquired company $197 million in revenue for 2016. This comes two months after Quidel completed an acquisition of InflammaDry(R) and AdenoPlus(R) Eye-Health Businesses. With Quidel acquiring so many companies, it is clear that the company is growing into a major player in the biotechnical market.
QDEL is on a clear upward trend following these news releases with no end in sight. Currently, QDEL is at a three year high with a pps (price per share) of 34.12. From 10/13/14, QDEL hit its high at the time of ~28.6 and then fell to its three year low of 14.16 on 2/15/16. From that date forward, the stock has enjoyed many volatile increases upward. With QDEL shattering its previous highest resistance line, the sky is currently the limit for this stock. With a gold cross spotted, QDEL is certainly enjoying a very bullish market.
Read More Here
Quidel is at a three year high with a pps (price per share) of 34.12
Quidel announced that they have entered into a definitive agreement to acquire Alere Triages' Assets
Made ~$118,189,000 in Gross Profits
The Global Biotechnical Market was valued at $270.5 Billion in 2013
Analysts gave QDEL an average estimate of ~$241.32 million for the expected total revenue in 2018.
Quidel Corporation (QDEL) is a biotechnical company that develops, manufactures, and markets their diagnostic testing solutions for infectious diseases, women's' health products, and gastrointestinal diseases. From their research and development efforts, Quidel has a wide range of products to offer. To begin with, they just received FDA Clearance and CLIA waiver for their award winning point-of-car Sofia 2 Instrument which is used for the rapid detection of respiratory syncytial virus (RSB). Also, the company has recently also gotten FDA Clearance to market their Solana C. difficile Assay for the detection of Clostridium difficile-infection (CDI). Their other products include QuickVue influenza, QuickVue RSV, Quidel Molecular RXV, and much more.
On July 17, 2017, Quidel announced that they have entered into a definitive agreement to acquire Alere Triages' Assets. This will allow Quidel to distribute the Triage MeterPro products and BNP assays which brought the acquired company $197 million in revenue for 2016. This comes two months after Quidel completed an acquisition of InflammaDry(R) and AdenoPlus(R) Eye-Health Businesses. With Quidel acquiring so many companies, it is clear that the company is growing into a major player in the biotechnical market.
QDEL is on a clear upward trend following these news releases with no end in sight. Currently, QDEL is at a three year high with a pps (price per share) of 34.12. From 10/13/14, QDEL hit its high at the time of ~28.6 and then fell to its three year low of 14.16 on 2/15/16. From that date forward, the stock has enjoyed many volatile increases upward. With QDEL shattering its previous highest resistance line, the sky is currently the limit for this stock. With a gold cross spotted, QDEL is certainly enjoying a very bullish market.
Read More Here
~The only thing standing between you and your goal is the bullshit story you keep telling yourself as to why you can't achieve it.~
- Wolf Of Wallstreet Film
[img]http://i.imgur.com/IcSt32B.jpg[
Recent QDEL News
- QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics • PR Newswire (US) • 04/20/2026 11:12:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 08:15:43 PM
- QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance • PR Newswire (US) • 04/15/2026 08:15:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 08:40:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 11:00:12 AM
- Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer • PR Newswire (US) • 03/24/2026 11:00:00 AM
- Faster Cardiac Answers with High‑Sensitivity Troponin • PR Newswire (US) • 02/19/2026 02:17:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/19/2026 02:45:21 AM
- QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference • PR Newswire (US) • 02/18/2026 09:05:00 PM
- QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio • PR Newswire (US) • 02/16/2026 06:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 09:21:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:07:04 PM
- QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 02/11/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 09:19:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:51:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:51:02 AM
- QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards • PR Newswire (US) • 02/03/2026 12:12:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 12:07:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 12:07:07 AM
- Strengthening the blood supply: Awareness, challenges and donor impact • PR Newswire (US) • 01/22/2026 12:12:00 PM
- QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 01/21/2026 12:00:00 PM
- Innovating Diagnostics and What's Next • PR Newswire (US) • 12/18/2025 02:17:00 PM
- QuidelOrtho To Participate In Upcoming Investor Conferences • PR Newswire (US) • 11/24/2025 12:00:00 PM
- The Power of Prevention: Detecting Diabetes Before It Strikes • PR Newswire (US) • 11/20/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 01:02:30 PM
